"10.1371_journal.pone.0147968","plos one","2016-01-28T00:00:00Z","Ludwig Rasche; Lisa Heiserich; Janina Ruth Behrens; Klaus Lenz; Catherina Pfuhl; Katharina Wakonig; René Markus Gieß; Erik Freitag; Caroline Eberle; Jens Wuerfel; Jan Dörr; Peter Bauer; Judith Bellmann-Strobl; Friedemann Paul; Dirk Roggenbuck; Klemens Ruprecht","NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany; Clinical and Experimental Multiple Sclerosis Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany; Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Medipan GmbH, Berlin-Dahlewitz, Germany; Department of Medical Biometrics and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Berlin, Germany; MIAC AG, Basel, Switzerland; Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin-Buch, Germany; Institute of Neuroradiology, Universitätsmedizin Göttingen, Göttingen, Germany; Faculty of Science, Brandenburg University of Technology Cottbus - Senftenberg, Senftenberg, Germany","Conceived and designed the experiments: DR KR PB LH LR. Performed the experiments: LR CE LH CP KW RMG EF JRB JBS. Analyzed the data: LR KL KR JW JRB JBS DR LH. Contributed reagents/materials/analysis tools: DR KR FP JD JW. Wrote the paper: LR KR DR. Critical revision of the manuscript for important intellectual content: LH KL CP KW RMG EF CE JW JD PB JBS FP JRB.","LR has received a travel grant from Bayer Healthcare unrelated to this study; LH is an employee of Medipan GmbH; JRB received travel support by Biogen Idec and Novartis; KL has nothing to disclose; CP has nothing to disclose; KW has nothing to disclose; RMG has received financial support from Novartis for travel and congress attendance; EF has nothing to disclose; CE is an employee of Medipan GmbH; JW is CEO of MIAC AG, Basel, Schweiz, he serves for Novartis and Biogen advisory boards, and has received speaker honoraria by Bayer, Biogen, Genzyme, Novartis and Teva. He is supported by the Bundesministerium für Wirtschaft (BMWi), the Deutsche Forschungsgemeinschaft (DFG), the Bundesministerium für Bildung und Forschung (BMBF Competence Network Multiple Sclerosis) and the Guthy Jackson Charitable Foundation; JD received research support from Novartis and Bayer Healthcare, speaker honoraria from Novartis, Teva, Genzyme, Biogen, and Bayer Healthcare, honoraria for advisory from Teva, Genzyme, and Bayer Healthcare, and travel support from Bayer Healthcare, Merck-Serono, and Novartis; PB is an employee of Medipan GmbH; JBS has received speaking fees and travel grants from Bayer Healthcare, sanofi-aventis/Genzyme, and Teva Pharmaceuticals unrelated to this study; FP has received travel grants, research support and personal compensation for activities with Alexion, Bayer, MerckSerono, Teva, Sanofi Genzyme, MedImmune, Chugai, BiogenIdec and Novartis and is supported by the Deutsche Forschungsgemeinschaft (DFG EXC257), the Bundesministerium für Bildung und Forschung (BMBF Competence Network Multiple Sclerosis) and the Guthy Jackson Charitable Foundation; DR is a shareholder of and has a managerial position at Medipan GmbH; KR received research support from Novartis as well as speaking fees and travel grants from Guthy Jackson Charitable Foundation, Bayer Healthcare, Biogen Idec, Merck Serono, sanofi-aventis/Genzyme, Teva, and Novartis; and is supported by the German Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis). Medipan GmbH provided support in the form of salaries for authors (LH, CE, PB, DR) and research materials. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.","2016","01","Ludwig Rasche","LR",16,TRUE,5,9,8,3,TRUE,TRUE,FALSE,0,NA,FALSE
